Table 1.
Patient demographics and tumor characteristics—combined cohort.
| Descriptor | Class 1A (n = 965) | Class 1B/2A (n = 226) | Class 2B (n = 70) | Combined (n = 1261) |
|---|---|---|---|---|
| Age (years), median (Range) | 60 (13–91) | 63 (19–95) | 67 (25–88) | 61 (13–95) |
| Sex | ||||
| Female | 299 (31.0%) | 52 (23.0%) | 14 (20.0%) | 365 (28.9%) |
| Male | 331 (34.3%) | 71 (31.4%) | 19 (27.1%) | 421 (33.4%) |
| Unknown | 335 (34.7%) | 103 (45.6%) | 37 (52.9%) | 475 (37.7%) |
| Tumor Location | ||||
| Extremity | 453 (46.9%) | 111 (49.1%) | 31 (44.3%) | 595 (47.2%) |
| Head and neck | 192 (19.9%) | 55 (24.3%) | 20 (28.6%) | 267 (21.2%) |
| Trunk | 320 33.2%) | 60 (26.5%) | 19 (27.1%) | 399 (31.6%) |
| Breslow thickness (mm), median (Range) | 0.6 (0.08–2.03) | 1.0 (0.1–2.0) | 1.2 (0.18–2.03) | 0.7 (0.08–2.03) |
| Ulceration | ||||
| No | 883 (91.5%) | 196 (86.7%) | 59 (84.3%) | 1138 (90.2%) |
| Yes | 19 (2.0%) | 11 (4.9%) | 7 (10.0%) | 37 (2.9%) |
| Unknown | 63 (6.5%) | 19 (8.4%) | 4 (5.7%) | 86 (6.8%) |
| Mitotic rate (1/mm2), median (Range) | 0.0 (0.0–10.0) | 1.0 (0.0–10.0) | 1.0 (0.0–10.0) | 0.0 (0.0–10.0) |
| Recurrence | ||||
| No | 940 (97.4%) | 205 (90.7%) | 57 (81.4%) | 1202 (95.3%) |
| Yes | 25 (2.6%) | 21 (9.3%) | 13 (18.6%) | 59 (4.7%) |
| Melanoma-specific death | ||||
| No | 960 (99.5%) | 222 (98.2%) | 64 (91.4%) | 1246 (98.8%) |
| Yes | 5 (0.5%) | 4 (1.8%) | 6 (8.6%) | 15 (1.2%) |
| T-stage | ||||
| T1a | 581 (60.2%) | 56 (24.8%) | 11 (15.7%) | 648 (51.4%) |
| T1b | 206 (21.3%) | 64 (28.3%) | 16 (22.9%) | 286 (22.7%) |
| T2a | 178 (18.4%) | 106 (46.9%) | 43 (61.4%) | 327 (25.9%) |
| AJCC 8th edition * | ||||
| Stage IA | 713 (73.9%) | 92 (40.7%) | 20 (28.6%) | 825 (65.4%) |
| Stage IB | 252 (26.1%) | 134 (59.3%) | 50 (71.4%) | 436 (34.6%) |
Abbreviation: AJCC, American Joint Committee on Cancer; * AJCC stage was determined using Breslow thickness and ulceration status.